CD226 and non-small cell lung carcinoma: In patients with early-stage NSCLC, tumor-infiltrating NK cells demonstrate diminished expression of activating receptors (NKp30, NKp80, CD16, and CD226) alongside reduced degranulation capacity and cytokine production39.